BMRN

Biomarin Pharmaceutical Inc

Add to Watchlist

Advanced Chart

59.270

+1.000(+1.720%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

59.730

Open

59.125

VWAP

59.16

Vol

3.49M

Mkt Cap

11.37B

Low

57.820

Amount

206.65M

EV/EBITDA(TTM)

13.07

Total Shares

189.88M

10.50B

EV/OCF(TTM)

14.99

P/S(TTM)

3.91

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

832.42M

+11.39%

1.067

+15.98%

797.85M

+6.99%

1.038

+14.06%

761.88M

+7%

1.028

+7.1%

Estimates Revision

The market is revising Downward the revenue expectations for BioMarin Pharmaceutical Inc. (BMRN) for FY2025, with the revenue forecasts being adjusted by -0.16% over the past three months. During the same period, the stock price has changed by -8.62%.

Revenue Estimates for FY2025

Revise Downward

-0.16%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.39%

In Past 3 Month

Stock Price

Go Down

-8.62%

In Past 3 Month

21 Analyst Rating

64.28% Upside

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 97.37 USD with a low forecast of 70.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

5 Hold

0 Sell

Strong Buy

64.28% Upside

Current: 59.270

Low

70.00

Averages

97.37

High

126.00

64.28% Upside

Current: 59.270

Low

70.00

Averages

97.37

High

126.00

Goldman Sachs

Salveen Richter

Strong Buy

Maintains

$124 → $104

2025-05-05

Reason

Goldman Sachs

Salveen Richter

Price Target

$124 → $104

2025-05-05

Maintains

Strong Buy

Reason

Citigroup

David Lebovitz

Hold

Maintains

$82 → $78

2025-05-02

Reason

Citigroup

David Lebovitz

Price Target

$82 → $78

2025-05-02

Maintains

Hold

Reason

Oppenheimer

Leland Gershell

Hold

Buy

Upgrades

$98

2025-02-24

Reason

Oppenheimer

Leland Gershell

Price Target

$98

2025-02-24

Upgrades

Hold

Buy

Reason

Oppenheimer upgraded BioMarin to Outperform from Perform with a $98 price target.

B of A Securities

Geoff Meacham

Strong Buy

Maintains

$99 → $103

2025-02-20

Reason

B of A Securities

Geoff Meacham

Price Target

$99 → $103

2025-02-20

Maintains

Strong Buy

Reason

Piper Sandler

Christopher Raymond

Buy

Maintains

$122 → $126

2025-02-20

Reason

Piper Sandler

Christopher Raymond

Price Target

$122 → $126

2025-02-20

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on BioMarin to $126 from $122 and keeps an Overweight rating on the shares following a Q4 top- and bottom-line beat and FY25 guidance that infers meaningful upside to consensus. With Voxzogo still showing robust growth and the legacy ERT/Palynziq business with meaningful growth potential, the firm likes BioMarin's chances at meeting or beating FY27 revenue guidance of over $4B. Coupling this with two meaningful pipeline updates this year, Piper thinks management continues to execute well across all aspects of the business.

UBS

Eliana Merle

Strong Buy

Maintains

$109 → $113

2025-02-20

Reason

UBS

Eliana Merle

Price Target

$109 → $113

2025-02-20

Maintains

Strong Buy

Reason

UBS analyst Eliana Merle raised the firm's price target on BioMarin to $113 from $109 and keeps a Buy rating on the shares. BioMarin reported a strong quarter, and Voxzogo still has ample room to grow from here, both in terms of greater penetration of the achondroplasia market and in expansion indications longer-term, the analyst tells investors in a research note. The firm thinks the opportunity for Voxzogo in indications beyond achondroplasia remains significantly underappreciated, and could be a $5B+ opportunity.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Biomarin Pharmaceutical Inc (BMRN.O) is 13.46, compared to its 5-year average forward P/E of 48.00. For a more detailed relative valuation and DCF analysis to assess Biomarin Pharmaceutical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

48.00

Current PE

13.46

Overvalued PE

73.93

Undervalued PE

22.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

81.64

Current EV/EBITDA

10.65

Overvalued EV/EBITDA

201.59

Undervalued EV/EBITDA

-38.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

6.89

Current PS

3.49

Overvalued PS

8.54

Undervalued PS

5.25

Financials

Annual

Quarterly

FY2025Q1

YoY :

+14.84%

745.15M

Total Revenue

FY2025Q1

YoY :

+185.35%

223.89M

Operating Profit

FY2025Q1

YoY :

+109.43%

185.69M

Net Income after Tax

FY2025Q1

YoY :

+106.52%

0.95

EPS - Diluted

FY2025Q1

YoY :

+1125.04%

157.63M

Free Cash Flow

FY2025Q1

YoY :

+0.65%

79.01

Gross Profit Margin - %

FY2025Q1

YoY :

+218.48%

21.02

FCF Margin - %

FY2025Q1

YoY :

+82.43%

24.92

Net Margin - %

FY2025Q1

YoY :

+129.73%

8.50

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

110.3K

USD

3-6

Months

91.9K

USD

6-9

Months

350.3K

USD

0-12

Months

64.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 404.87% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

652.4K

Volume

6-9

Months

0.0

Volume

0-12

Months

129.2K

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.7M

Volume

Months

6-9

0.0

Volume

Months

0-12

4.9M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

110.3K

USD

3-6

Months

91.9K

USD

6-9

Months

350.3K

USD

0-12

Months

64.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BMRN News & Events

Events Timeline

2025-05-16 (ET)

2025-05-16

13:26:28

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

2025-05-16

09:29:29

BioMarin says Inozyme deal to strengthen enzyme therapies portfolio

2025-05-16

07:39:36

BioMarin's acquisition of Inozyme to strengthen enzyme therapies portfolio

News

8.5

05-16NASDAQ.COM

BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash

8.5

05-16Newsfilter

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

8.5

05-16SeekingAlpha

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

People Also Watch

BXP

Boston Properties Inc

Aurora Innovation Inc

Stifel Financial Corp

FAQ

What is Biomarin Pharmaceutical Inc (BMRN) stock price today?

The current price of BMRN is 59.27 USD — it has increased 1.72 % in the last trading day.

BMRN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BMRN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Biomarin Pharmaceutical Inc (BMRN) stock price today?

What is Biomarin Pharmaceutical Inc (BMRN)'s business?

What is the price predicton of BMRN Stock?

What is Biomarin Pharmaceutical Inc (BMRN)'s revenue for the last quarter?

What is Biomarin Pharmaceutical Inc (BMRN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Biomarin Pharmaceutical Inc (BMRN)'s fundamentals?

How many employees does Biomarin Pharmaceutical Inc (BMRN). have?

What is Biomarin Pharmaceutical Inc (BMRN) market cap?